A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

Study Summary

The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.

Conditions

Erosive Esophagitis Heartburn Symptomatic Non-erosive Gastroesophageal Reflux Disease Helicobacter Pylori Infection

Interventions / Drugs

Vonoprazan

View on ClinicalTrials.gov ↗

Sponsor

PHAT

Phathom Pharmaceuticals

D41/100

Study Details

Enrollment728 participants

Primary Completion—

Lead SponsorPhathom Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:24:17.294739+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.